Profile Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two wholly-owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune/Roche) having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013.

Array BioPharma Fact Sheet	Array BioPharma Investor Presentation	Array BioPharma 2012 Annual Report

Receive E-mail Alerts

RSS Feeds

Recent News

More >>

05/15/13 Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting 05/08/13 Array BioPharma to Present at the Bank of America Merrill Lynch Healthcare Conference and the UBS Global Healthcare Conference 05/06/13 Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013 05/06/13 Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer

Upcoming Events

More >>

Date Title 05/21/13 8:30 a.m. ET Array BioPharma Inc. at UBS Global Healthcare Conference Location Sheraton New York Hotel New York, NY US

Primary IR Contacts Michael Carruthers Chief Financial Officer Phone: (303) 381-6663 E-mail: Michael.Carruthers@arraybiopharma.com Tricia Haugeto Senior Manager, Communications Phone: (303) 386-1193 E-mail: Tricia.Haugeto@arraybiopharma.com	Transfer Agent American Stock Transfer and Trust Company 59 Maiden Lane Plaza Level New York, NY 10038 Phone: (800) 937-5449 Fax: (718) 236-4588 E-mail: Info@amstock.com Website: http://www.amstock.com
Legal Gross Hartman LLC 1877 Broadway, Suite 601 Boulder, CO 80302 Phone: (303) 926-4823	Accountants KPMG LLP 707 Seventeenth Street, Suite 2700 Denver, CO 80202 Phone: (303) 295-5572

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.